Trimetazidine Dihydrochloride is a fatty acid oxidation inhibitor as an anti-ischemic (anti-anginal) metabolic agent, improving myocardial glucose utilization through inhibition of fatty acid metabolism and and preventing macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin. References: Su Q, Li L, Zhao J, Sun Y, Yang H. Effects of trimetazidine on periprocedural microRNA-21 expression by CD4+ T lymphocytes in patients with unstable angina pectoris. Oncotarget. 2017 Sep 18;8(62):104992-104999. doi: 10.18632/oncotarget.20975. eCollection 2017 Dec 1. PubMed PMID: 29285227; PubMed Central PMCID: PMC5739614.

纯度：≥98%

CAS：13171-25-0